AKT1 and neoplasm: The fact that this gene expression pattern is seen in tumors treated with both anti-NF-κB agents suggests that this mechanism of resistance may be generalizable, and implies that combination therapy with agents that block Bcl2 and/or AKT may result in additive or even synergistic anti-tumor activity, and this will be investigated in future work.